[go: up one dir, main page]

WO1998010787A3 - Therapie a but immunitaire - Google Patents

Therapie a but immunitaire Download PDF

Info

Publication number
WO1998010787A3
WO1998010787A3 PCT/IB1997/001086 IB9701086W WO9810787A3 WO 1998010787 A3 WO1998010787 A3 WO 1998010787A3 IB 9701086 W IB9701086 W IB 9701086W WO 9810787 A3 WO9810787 A3 WO 9810787A3
Authority
WO
WIPO (PCT)
Prior art keywords
immune
host
interleukin
sequences
disease
Prior art date
Application number
PCT/IB1997/001086
Other languages
English (en)
Other versions
WO1998010787A2 (fr
Inventor
Patrick T Prendergast
Original Assignee
Patrick T Prendergast
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Patrick T Prendergast filed Critical Patrick T Prendergast
Priority to CA002265885A priority Critical patent/CA2265885A1/fr
Priority to IL12880697A priority patent/IL128806A0/xx
Priority to NZ335039A priority patent/NZ335039A/en
Priority to JP51343598A priority patent/JP2001503613A/ja
Priority to EP97939105A priority patent/EP0929568A2/fr
Priority to AU41320/97A priority patent/AU4132097A/en
Publication of WO1998010787A2 publication Critical patent/WO1998010787A2/fr
Publication of WO1998010787A3 publication Critical patent/WO1998010787A3/fr
Priority to SE9900812A priority patent/SE9900812L/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/06—Tripeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A61K38/2026—IL-4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A61K38/2066—IL-10
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/385—Haptens or antigens, bound to carriers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A61P33/06—Antimalarials
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4715—Pregnancy proteins, e.g. placenta proteins, alpha-feto-protein, pregnancy specific beta glycoprotein
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/5428—IL-10
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/5434—IL-12
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/10—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses
    • C07K16/1036—Retroviridae, e.g. leukemia viruses
    • C07K16/1045—Lentiviridae, e.g. HIV, FIV, SIV
    • C07K16/1063—Lentiviridae, e.g. HIV, FIV, SIV env, e.g. gp41, gp110/120, gp160, V3, PND, CD4 binding site
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • C07K16/247—IL-4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K4/00—Peptides having up to 20 amino acids in an undefined or only partially defined sequence; Derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/08—Tripeptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56983—Viruses
    • G01N33/56988—HIV or HTLV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/15011—Lentivirus, not HIV, e.g. FIV, SIV
    • C12N2740/15022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16111—Human Immunodeficiency Virus, HIV concerning HIV env
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16111—Human Immunodeficiency Virus, HIV concerning HIV env
    • C12N2740/16122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Epidemiology (AREA)
  • Virology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Hematology (AREA)
  • Toxicology (AREA)
  • Microbiology (AREA)
  • Biomedical Technology (AREA)
  • AIDS & HIV (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Oncology (AREA)
  • Urology & Nephrology (AREA)
  • Mycology (AREA)
  • Analytical Chemistry (AREA)
  • Pregnancy & Childbirth (AREA)
  • Reproductive Health (AREA)
  • Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)

Abstract

L'invention concerne une séquence d'acides aminés présentant des groupes de paires d'ions spécifiques (ponts) ceints au moins d'un côté par des segments transmembranaires hydrophobes non polaires, en tant que mécanisme utilisé par de nombreux agents infectieux et plusieurs facteurs d'inhibition de la cytokine, tels que l'interleukine 10, le facteur d'inhibition de la prolactine et l'alpha-foeto-protéine. Ladite séquence n'est pas seulement utilisée pour amoindrir les défenses immunitaires des hôtes mais également pour permettre l'infection de tissus lymphoïdes cibles. Il a été prouvé que certains vaccins, lorsqu'ils sont inoculés à un hôte, produisent un certaine gamme d'anticorps neutralisants mais n'empêchent pas l'infection lorsque cet hôte est ensuite exposé à un organisme infectieux vivant. Dans la thérapie de l'invention, lorsque l'inoculation de ce type de vaccin est combinée à une immunisation passive au moyen d'anticorps mono ou polyclonaux dirigés contre lesdites séquences d'acides aminés, l'hôte est capable de surmonter l'agression infectieuse. L'invention se rapporte à l'utilisation thérapeutique d'anticorps mono ou polyclonaux dirigés contre lesdites séquences spécifiques, comme traitement du syndrome d'immunodéficience acquise (SIDA) et d'autres états pathologiques qui persistent en raison de la présence d'un facteur d'inhibition de la cytokine d'origine virale, bactérienne ou provenant de l'hôte, tel que le syndrome de fatigue chronique dans lequel les molécules d'imitation de l'interleukine 10 sont responsables d'une multitudes de symptômes identifiés comme indicateurs de l'encéphalomyélite. L'invention se rapporte à l'utilisation thérapeutique d'anticorps mono ou polyclonaux dirigés contre ces séquences d'acides aminés spécifiques, sous forme de thérapie associée au moyen de vaccins et d'agents antiviraux pour la prévention des effets secondaires de certains agents de modulation des défenses immunitaires et antiviraux (ex: DHEA et IL-12) qui provoquent la production accrue de molécules d'imitation de l'interleukine 10 ou de l'alpha-foetoprotéine pendant la thérapie. L'invention se rapporte encore à l'utilisation thérapeutique de ces séquences spécifiques, soit isolées de la source de l'organisme source, soit produites par synthèse directe ou synthèse de protéines recombinaison. Ces peptides, lorsqu'ils sont administrés à un patient souffrant d'une maladie auto-immune, tels que, entre autres, la sclérose en plaques, le lupus érythémateux (lupus érythémateux systémique), le diabète ou la polyarthrite rhumatoïde ou à des receveurs de transplant, permettent de modifier l'état immunitaire du patient de sorte que soit produite une réponse immunitaire dépendante de l'anticorps Th2 et que soit inhibée l'attaque immunitaire de Th1 (dépendant des lymphocytes) qui se manifeste dans ces types de déficiences immunitaires, telles que la sclérose en plaques et la réaction du greffon contre l'hôte. Certaines affections dermatologiques qui sont aujourd'hui traitées au moyen de crèmes et d'onguents corticostéroïdes peuvent être également traitées avec succès par le remplacement des corticostéroïdes par ces séquences immunosuppressives d'imitation de l'interleukine 10 et de l'alpha-foetoprotéine de l'invention.
PCT/IB1997/001086 1996-09-11 1997-09-10 Therapie a but immunitaire WO1998010787A2 (fr)

Priority Applications (7)

Application Number Priority Date Filing Date Title
CA002265885A CA2265885A1 (fr) 1996-09-11 1997-09-10 Therapie a but immunitaire
IL12880697A IL128806A0 (en) 1996-09-11 1997-09-10 Compositions for immune therapy
NZ335039A NZ335039A (en) 1996-09-11 1997-09-10 Enhancing immune response by administering antibody raised to amino acid sequences with specific ion bridge pair arrays
JP51343598A JP2001503613A (ja) 1996-09-11 1997-09-10 免疫管理療法
EP97939105A EP0929568A2 (fr) 1996-09-11 1997-09-10 Compositions pharmaceutiques pour therapie a but immunitaire
AU41320/97A AU4132097A (en) 1996-09-11 1997-09-10 Immune direction therapy
SE9900812A SE9900812L (sv) 1996-09-11 1999-03-08 Riktad immunoterapi

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US2518096P 1996-09-11 1996-09-11
US60/025,180 1996-09-11

Publications (2)

Publication Number Publication Date
WO1998010787A2 WO1998010787A2 (fr) 1998-03-19
WO1998010787A3 true WO1998010787A3 (fr) 1998-07-30

Family

ID=21824510

Family Applications (2)

Application Number Title Priority Date Filing Date
PCT/IB1996/000945 WO1998010792A1 (fr) 1996-09-11 1996-09-13 Therapie a but immunitaire
PCT/IB1997/001086 WO1998010787A2 (fr) 1996-09-11 1997-09-10 Therapie a but immunitaire

Family Applications Before (1)

Application Number Title Priority Date Filing Date
PCT/IB1996/000945 WO1998010792A1 (fr) 1996-09-11 1996-09-13 Therapie a but immunitaire

Country Status (9)

Country Link
EP (1) EP0929568A2 (fr)
JP (1) JP2001503613A (fr)
CN (1) CN1230195A (fr)
AU (2) AU6887096A (fr)
CA (1) CA2265885A1 (fr)
IL (1) IL128806A0 (fr)
NZ (1) NZ335039A (fr)
SE (1) SE9900812L (fr)
WO (2) WO1998010792A1 (fr)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8283165B2 (en) 2008-09-12 2012-10-09 Genvault Corporation Matrices and media for storage and stabilization of biomolecules
US8431384B2 (en) 2004-05-24 2013-04-30 Genvault Corporation Stable protein storage and stable nucleic acid storage in recoverable form

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000009150A2 (fr) * 1998-08-17 2000-02-24 Prendergast Patrick T Cytokines et recepteur de cytokines, agoniste, antagoniste et/ou combinaison d'anticorps a usage therapeutique
AU1579700A (en) * 1998-12-15 2000-07-03 Hollis-Eden Pharmaceuticals Cytokine combination therapy
CA2403196A1 (fr) * 2000-03-14 2001-09-20 National Jewish Medical And Research Center Procede et composition pour traiter une hyperreactivite bronchique
FI118263B (fi) 2002-10-09 2007-09-14 Timo Kalevi Korpela Kaspaasiaktiivisuutta säätelevät peptidit
EA008925B1 (ru) * 2004-12-14 2007-08-31 Товарищество С Ограниченной Ответственностью "Реал Мед Компани" Способ коррекции иммунного состояния организма при сахарном диабете
DE602006019567D1 (de) * 2005-03-22 2011-02-24 Rohto Pharma Peptide, die die collagen- oder hyaluronsäureproduktion erhöhen
US7553932B1 (en) 2005-04-25 2009-06-30 La Jolla Institute For Allergy And Immunology Methods of treating viral infection with IL-10 receptor antagonists
US8932829B2 (en) 2005-07-07 2015-01-13 Elena Dudich Recombinant alpha-fetoprotein and compositions thereof
EP2989120A4 (fr) * 2013-04-25 2017-04-19 Carmel-Haifa University Economic Corp. Peptides anti-inflammatoires synthétiques et leur utilisation
CN103275222B (zh) * 2013-05-15 2014-04-16 中山康方生物医药有限公司 一种阻断白介素12 p40功能的单克隆抗体及其编码基因和应用
CN114163493B (zh) * 2021-11-18 2023-09-15 浙大宁波理工学院 一种可作为5型磷酸二酯酶抑制剂的多肽及其应用

Citations (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0056249A2 (fr) * 1981-01-09 1982-07-21 New York Blood Center, Inc. Composition synthétique d'antigènes et leur procédé de préparation
WO1988005783A1 (fr) * 1987-01-28 1988-08-11 Ortho Pharmaceutical Corporation Peptides immunodepresseurs et leurs procedes d'utilisation
EP0287226A1 (fr) * 1987-03-23 1988-10-19 Hiver Limited Vaccin
US4822606A (en) * 1986-04-07 1989-04-18 Duke University Immunosuppressive synthetic peptides and analogs thereof based on retroviral envelope sequences
EP0323424A2 (fr) * 1987-12-30 1989-07-05 Jonas Blomberg Peptides correspondant à HIV-env 583-599, leurs analogues et utilisation de ces peptides
WO1991014451A1 (fr) * 1990-03-26 1991-10-03 Schering Corporation Antagonistes contre la proteine bcrf1 destines au traitement d'infections provoquees par le virus d'epstein-barr
WO1993011157A1 (fr) * 1991-11-27 1993-06-10 The Council Of The Queensland Institute Of Medical Research VACCIN ET PEPTIDES CONTRE LA MALARIA COMPRENANT UN EPITOPE DE CELLULE T HUMAINE DE PROTEINE CIRCUMSPOROZOITE DE $i(P.VIVAX)
WO1995004075A1 (fr) * 1993-07-28 1995-02-09 Medvet Science Pty. Ltd. Antagonistes de facteurs de croissance hematopoietique
WO1995019568A1 (fr) * 1994-01-14 1995-07-20 Matthias Rath Oligopeptides signaux hydrophiles et leurs procedes d'utilisation a des fins therapeutiques
WO1997026279A1 (fr) * 1996-01-18 1997-07-24 Steeno Research Group A/S Analogues synthetiques d'il-10

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU679908B2 (en) * 1992-03-04 1997-07-17 Schering Corporation Use of interleukin-10 to suppress graft-vs.-host disease
AU3801193A (en) * 1992-03-20 1993-10-21 Schering Corporation Use of interleukin-10 to induce the production of interleukin-1 receptor antagonist
EP0667789A1 (fr) * 1992-09-18 1995-08-23 Schering Corporation Retablissement de l'immunosuffisance des lymphocytes t auxiliaires chez des patients contamines par le vih

Patent Citations (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0056249A2 (fr) * 1981-01-09 1982-07-21 New York Blood Center, Inc. Composition synthétique d'antigènes et leur procédé de préparation
US4822606A (en) * 1986-04-07 1989-04-18 Duke University Immunosuppressive synthetic peptides and analogs thereof based on retroviral envelope sequences
WO1988005783A1 (fr) * 1987-01-28 1988-08-11 Ortho Pharmaceutical Corporation Peptides immunodepresseurs et leurs procedes d'utilisation
EP0287226A1 (fr) * 1987-03-23 1988-10-19 Hiver Limited Vaccin
EP0323424A2 (fr) * 1987-12-30 1989-07-05 Jonas Blomberg Peptides correspondant à HIV-env 583-599, leurs analogues et utilisation de ces peptides
WO1991014451A1 (fr) * 1990-03-26 1991-10-03 Schering Corporation Antagonistes contre la proteine bcrf1 destines au traitement d'infections provoquees par le virus d'epstein-barr
WO1993011157A1 (fr) * 1991-11-27 1993-06-10 The Council Of The Queensland Institute Of Medical Research VACCIN ET PEPTIDES CONTRE LA MALARIA COMPRENANT UN EPITOPE DE CELLULE T HUMAINE DE PROTEINE CIRCUMSPOROZOITE DE $i(P.VIVAX)
WO1995004075A1 (fr) * 1993-07-28 1995-02-09 Medvet Science Pty. Ltd. Antagonistes de facteurs de croissance hematopoietique
WO1995019568A1 (fr) * 1994-01-14 1995-07-20 Matthias Rath Oligopeptides signaux hydrophiles et leurs procedes d'utilisation a des fins therapeutiques
WO1997026279A1 (fr) * 1996-01-18 1997-07-24 Steeno Research Group A/S Analogues synthetiques d'il-10

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
M. RATH: "Cationic-anionic and anionic-cationic oligopeptides in apoprotein-A and other proteins as modulators of protein action and of biological communication", JOURNAL OF APPLIED NUTRITION, vol. 44, no. 3-4, 1992, LA HABRA US, pages 62 - 69, XP002051963 *

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8431384B2 (en) 2004-05-24 2013-04-30 Genvault Corporation Stable protein storage and stable nucleic acid storage in recoverable form
US8283165B2 (en) 2008-09-12 2012-10-09 Genvault Corporation Matrices and media for storage and stabilization of biomolecules
US8951719B2 (en) 2008-09-12 2015-02-10 Gentegra, LLC. Matrices and media for storage and stabilization of biomolecules
US9637513B2 (en) 2008-09-12 2017-05-02 Gentegra Llc Matrices and media for storage and stabilization of biomolecules
US10160997B2 (en) 2008-09-12 2018-12-25 Gentegra Llc Matrices and media for storage and stabilization of biomolecules

Also Published As

Publication number Publication date
EP0929568A2 (fr) 1999-07-21
NZ335039A (en) 2001-04-27
AU4132097A (en) 1998-04-02
JP2001503613A (ja) 2001-03-21
AU6887096A (en) 1998-04-02
WO1998010792A1 (fr) 1998-03-19
IL128806A0 (en) 2000-01-31
WO1998010787A2 (fr) 1998-03-19
CN1230195A (zh) 1999-09-29
CA2265885A1 (fr) 1998-03-19
SE9900812D0 (sv) 1999-03-08
SE9900812L (sv) 1999-03-08

Similar Documents

Publication Publication Date Title
WO1998010787A3 (fr) Therapie a but immunitaire
CA2299677A1 (fr) Preparation et utilisation de constructions de la proteine m2 recombinante du virus grippal a et vaccins correspondants
Cardani et al. Oral administration of interleukin-10 and anti-IL-1 antibody ameliorates experimental intestinal inflammation
US9714272B2 (en) Recombinant proteins of parapdxvirus ovis and pharmaceutical compositions therefrom
CA2397675A1 (fr) Souche d'un virus modifie de vaccine ankara (mva)
JPH07503851A (ja) 改良インターフェロン及びヒトの末梢血液白血球からのその製造方法
WO2015109931A1 (fr) Protéine de fusion tim-3 humaine capable de bloquer une voie de signalisation tim-3
KR20010030563A (ko) 인터페론 칸센서스 및 인터루킨-1 수용체 길항물질을 포함하는 다발성경화증을 치료하기 위한 제약학적 조성물
EP0262710A1 (fr) Utilisation d'un peptide pour la préparation de compositions pour le soulagement, le traitement ou le diagnostique de maladies autoimmunes, notamment des affections arthritiques, et de composés dérivés dudit peptide, des microorganismes synthétisant ledit peptide ou de composés dérivés dudit peptide, ainsi que des compositions pharmaceutiques et diagnostiques et des kits de tests
US10884000B2 (en) Method of monitoring the efficacy of the anti-clever-1 therapy in cancer
CN113633764A (zh) 一种含佐剂的新冠dna疫苗
US20060198834A1 (en) Chaperonin 10 immunosuppression
JP2010535504A5 (fr)
US20030198624A1 (en) Method of treating allergic disease and asthma by recombinant adenovirus- and adeno-associated virus- mediated IFN-gamma gene transfer
US11976108B2 (en) Modified anti-inflammatory proteins and method of use
WO2003018606A3 (fr) Peptides derives de la caseine et leurs utilisations therapeutiques
JPH01104021A (ja) 血小板第４因子のペプチドフラグメントを含む組成物及び抑制免疫応答を回復させる方法
WO1993014206A3 (fr) Peptides synthetiques destines a un vaccin contre la rubeole
WO2003063786A3 (fr) Methodes et compositions permettant de distribuer des acides nucleiques et/ou des proteines au systeme respiratoire
WO2010079511A4 (fr) Nanopeptides dérivés d'un colostrum mammalien pour infections virales et récurrentes à large spectre avec leur procédé d'isolement
EP2647645A1 (fr) Protéines recombinées de Parapoxvirus ovis et compositions pharmaceutiques produites à partir de celles-ci
RU2076715C1 (ru) Способ получения препарата "аффинолейкин" для противоинфекционной иммунотерапии
EP0351876A2 (fr) Composition pour augmenter l'effet de vaccination
WO2024186780A3 (fr) Compositions et méthodes de traitement et de prévention du virus de la fièvre hémorragique de crimée-congo
EP2351769A2 (fr) Protéines recombinées de Parapoxvirus ovis et compositions pharmaceutiques produites à partir de celles-ci

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 97197816.6

Country of ref document: CN

AK Designated states

Kind code of ref document: A2

Designated state(s): AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GE GH HU ID IL IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG US UZ VN YU ZW AM AZ BY KG KZ MD RU TJ TM

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH KE LS MW SD SZ UG ZW AT BE CH DE DK ES FI FR GB GR IE IT LU MC

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
121 Ep: the epo has been informed by wipo that ep was designated in this application
AK Designated states

Kind code of ref document: A3

Designated state(s): AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GE GH HU ID IL IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG US UZ VN YU ZW AM AZ BY KG KZ MD RU TJ TM

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH KE LS MW SD SZ UG ZW AT BE CH DE DK ES FI FR GB GR IE IT LU MC

ENP Entry into the national phase

Ref document number: 2265885

Country of ref document: CA

Ref document number: 2265885

Country of ref document: CA

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 99008120

Country of ref document: SE

WWP Wipo information: published in national office

Ref document number: 99008120

Country of ref document: SE

ENP Entry into the national phase

Ref document number: 1998 513435

Country of ref document: JP

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 335039

Country of ref document: NZ

WWE Wipo information: entry into national phase

Ref document number: 1997939105

Country of ref document: EP

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWP Wipo information: published in national office

Ref document number: 1997939105

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 09254626

Country of ref document: US

WWW Wipo information: withdrawn in national office

Ref document number: 1997939105

Country of ref document: EP